Patient groups prone to polypharmacy and special subpopulations are susceptible to suboptimal treatment. Refined dosing in special populations is imperative to improve therapeutic response and/or lowering the risk of toxicity. Model-informed precision dosing (MIPD) may improve treatment outcomes by achieving the optimal dose for an individual patient. There is however relatively little published evidence of large-scale utility and impact of MIPD, where it is often implemented as local collaborative efforts between academia and healthcare.
practice. It is hoped that the report provides a roadmap to advance the position of MIPD to a common clinical practice under the umbrella of precision medicine.
BACKGROUND TO MODEL-INFORMED PRECISION DOSING
The goal of MIPD is to improve drug treatment outcomes in patients by achieving the optimal balance between efficacy and toxicity for the individual patient. The approach is based on the available information about the patient and the disease that they are treated for, comorbid diseases afflicting the patient, and the medication(s) they are receiving. The concept is inclusive of various modelling approaches, e.g., pharmacometrics (mathematical models of biology, pharmacology and physiology) as well as other modelling approaches (regression models, decision trees and other algorithms). The most suitable approach is likely to be determined by the goal, amount of available information about the patient and the drug, and performance of the model. Current dosing recommendations are determined by analysis of late stage (phases 2-4) clinical trial data which often include limited permutations of dosage regimens amongst vast number of possibilities. For certain drugs, the treatment effect can be improved by assigning the dose to be the function of a single covariate in the drug label, e.g., body weight (e.g., heparins) (1) or renal function (e.g., oseltamivir) (2). It is however less common to see dosing guidance for special patient populations (e.g., paediatrics, obesity or pregnancy) or dose regimens where more than one factor determines dose selection, e.g., vancomycin dosed in paediatrics based on age, weight and renal function (3, 4), or ganciclovir dosed adjusted by This article is protected by copyright. All rights reserved.
bodyweight and renal function (5). The absence of dosing recommendations translates to highly variable practices in clinical care particularly amongst the so called 'complex patients', leading to an increased risk of toxicity or suboptimal therapy, e.g., the reported high variability in local guidance and practices on dosing antibiotics in neonates in the UK and France (6, 7). Similarly, it is almost two decades since it was shown that in hospitalised patients adverse drug reactions (ADRs) may rank as high as the fourth leading cause of death in the United States (8). Management of dosing in special populations, polypharmacy and drug-drug interactions (DDIs) in the elderly may be aided by integrating MIPD into healthcare.
In May 2016 a Healthcare Summit was held in Cheshire, UK, to discuss for the first time the opportunities and challenges in "Model-informed precision dosing" (MIPD). During the meeting, many of the experts in the field exchanged views from clinical, academic, industrial and legal/regulatory perspectives on the subject matter. The meeting was a timely follow on to recent initiatives on precision medicine (9). The current and future role of MIPD in healthcare as a necessary element in the wider context of precision medicine was debated. Case examples of MIPD were highlighted in several areas, including but was not limited to:
• DDIs and HIV (human immunodeficiency virus) drug treatment:
o Predictability of metabolic DDIs -Experience from Geneva Hospital (10).
• Oncology:
o Paediatric oncology -Exposure of actinomycin D (11), o Dose optimisation of monoclonal antibodies (12), o Dose personalisation in haematopoietic cell transplant patients (13).
• Paediatric dose adjustments: o Drug exposure in heart failure patients (28).
Breakout sessions were hosted on the topic of how best to implement MIPD in healthcare with a view to answer the motion for the debate on "Why MIPD has not yet become common clinical reality?".
Against the background of the ongoing interest in precision medicine, and the utility for precision dosing under such a framework, we review here this meeting's outcomes to facilitate further discussion and help define the future direction on increased integration of MIPD into healthcare. This report also serves as an extension to previous discussions on the role of model-informed approaches to dosing in special populations from a regulatory and industry perspective during drug development (29, 30).
SETTING THE SCENE: CURRENT STATUS OF MODEL-INFORMED PRECISION

DOSING
In contrast to a one-size-fits-all approach to drug treatment where a drug or set of drugs are given for a certain disease (treating the disease), personalised medicine is designed to treat the patient who has the disease and hence it provides a therapeutic recommendation for the individual patient based on their characteristics and specific needs (e.g., finer diagnoses and sub-categorisation of the disease, age, body size, organ function, genetics of drug receptors and enzymes and transporters, drug interactions). Precision dosing lies within this broader concept and encompasses the process whereby the chosen drug therapy is modified to optimally treat an individual patient. The lack of specific This article is protected by copyright. All rights reserved.
dosing recommendations for more complex scenarios necessitates clinicians to use their previous experience to personalise dosing before or after the start of treatment based on the patient response, in a process which can be called 'in cerebro' modelling, as opposed computer-based 'in silico' modelling. However, the process applied by an individual physician may not be uniformly defined and applied when new cases arise.
The concept of precision dosing has been reinvigorated recently with the emergence of more affordable technology for genetic testing, the increasing availability of 'big data' and awareness that special populations often require optimisation to attain the desirable treatment effect (9, 31). Clinical trials have traditionally aimed to answer the question whether a label-defined dose regimen offers a positive risk-benefit profile across a protocol-defined population sample. The therapeutic response surface, introduced by Sheiner (1991) (32), describes the balance between efficacy and toxicity to depend on both drug exposure and patient characteristics. Where current phase 3 clinical trials characterise the average treatment-effect relationship in a controlled sample, it is however wellrecognised that the actual patient may differ because of the disease, underlying co-morbidities or DDIs (see 'randomised clinical trials', Figure 1 ).
Given the multiple levels of information that can influence an individual's dose response, common steps such as scaling by body weight, are unlikely to always address this question to a sufficient extent and in some instances (e.g., obesity) may in fact worsen the situation. Statistical analysis and population pharmacokinetic and dynamic (pop-PK/PD) modelling enables, in principle, the interpolation of the observed treatment response in randomised clinical trials as a function of multiple covariates (see 'population PKPD', Figure 1 ). That being said, sometimes, in order to optimally identify a regimen in patients falling outside the tested response and patient characteristics space, extrapolation of exposure and/or response is required under the assumption that PK/PD is constant over time and between subsets of patients. The latest PDUFA (Prescription Drug User Fee Act) VI strategy document for 2018-2022 (33) has specified the use of such relationships as a potential area of further research for justifying approval of doses or dosage regimens which were not tested in the clinical trial setting but which can be derived from models built on other doses and regimens studied.
This article is protected by copyright. All rights reserved.
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Mechanistic modelling, such as physiologically-based pharmacokinetic (PBPK) M&S, enables extrapolation by using information about the physiology and the drug (see 'in silico studies', Figure   1 ). Hence, model-informed approaches provide a rationale to precise dosing for an individual, as recognised by Dr Lewis B. Sheiner and Dr Roger W. Jelliffe as early as the 1960s (34, 35), and since then integrated into specific clinical decision tools (36-40). To mitigate off-label use, regulatory agencies have detailed label requirements which advise on dosing in relevant patient populations.
Dosing recommendations in the label can be based on the full body of available scientific evidence, analysed by in silico models as applicable, and not necessarily via clinical trials dedicated to a unique target population of patients, where the performed trials may be considered narrow by necessity.
There has been an increase in the use of modelling to inform drug labelling over the last decade, mainly for interpolation of the magnitude of metabolic DDIs, where 61% of applications of PBPK M&S were dedicated to the prediction of DDIs (29, 41, 42). Nonetheless, when dedicated studies are considered as the norm to provide dosing guidance it may lead to imprecise (and off-label) dosing in healthcare for special populations not explicitly addressed in the label, as indicated recently by Jadhav et al. (29) , keeping in mind that it is practically impossible to conduct specific studies for all the permutation of possible combinations of co-morbidities. Dosing of special populations in clinical practice relies heavily on local guidance or is left to the discretion of the clinician (7). Dosing recommendations in special populations, e.g., children or pregnant women, tend to err on the side of "caution" rather than being informed via evidence-based medicine (29). This caution often results in a label with either no mention of the specific population or a statement disclosing that the population was not studied, resulting in the prescriber making no dose adjustment, seeking alternative and possibly inferior therapy, or simply withholding the drug. 
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An MIPD approach is not an end in itself but rather a tool or guide towards optimal patient outcomes.
It is associated with certain criteria that should be fulfilled. The first prerequisite is the existence of a scientific rationale for dose selection, such as the existence of a well-defined concentration target with acceptable error (the therapeutic window), which maximises the chance of therapeutic success and minimises concentration-related toxicity. The therapeutic target should be determined by best available measurement of efficacy/toxicity, whether directly or through a validated biomarker.
Further, the lack of clinical data in a specific population, a narrow therapeutic window, inadequacy of allometric scaling methods (particularly in young children and obese patients) (46), impact of disease or treatment, the cost of relative overdosing of expensive compounds (e.g., monoclonal antibodies) A formal representation of MIPD is of benefit to highlight some of the important, but at times overlooked, milestones to implementing the approach in healthcare. For instance, the paradigm of 'predict, learn, confirm-implement' (Figure 3) is a requisite to the use of drug-independent (i.e., systems data on patient physiology) and drug-dependent information, together with available clinical data to inform model structure and parameterisation (see 'Data', Figure 3 ). Dependency on data varies between MIPD modelling methods, as determined by the conceptual approach and its complexity (i.e., decision trees, regression models, compartmental or mechanistic models). As a general guidance, models for precision dosing should undergo internal validation to diagnose any model misspecifications and external validation to test performance in a population sample different than the one used to develop the model. Prospective clinical evaluation is key to the process and should be carried out to evaluate the benefit of the MIPD approach over current best practice (see 'Validation', In many instances, precision dosing may be rephrased to what the right dose is for a given 'representative of a special subpopulation', once the target exposure in a reference population is known. Mechanistic models, such as PBPK, allow for extrapolation of exposure from patients represented in Phase 2-3 efficacy-safety studies to special populations through perturbation of model structure or parameters, as seen in cases such as: pregnancy, obesity, and for DDIs (10, 23, 25, 59, 60). Although currently PBPK M&S may be considered the best suited alternative for prediction/extrapolation of initial dosing in a drug-population combination that has not been previously studied, ability to incorporate all the patient information seamlessly from the patient records at the point of care is not in place. Moreover, this assumes that pharmacokinetics is the main determinant of inter-population differences (24). With increased ability to measure more individual patient covariates such as genotyping and metabolomics profiles, it is entirely possible for a PBPK model to serve as a Bayesian prior that can be updated to a Bayesian posterior model of the individual, suitable for dosing control (61) . This is a marriage of "bottom-up" (PBPK) and "topdown" (population approaches) in a so called "middle-out" approach (62).
Model-informed dosage regimens reconcile internally validated models with dose banding based on the identified covariates which were recognised by statistical analysis and can be of value to guide dosing of special populations in clinical practice in the absence of other evidence. The approach has been successfully used for dosing of morphine, amikacin and vancomycin in paediatrics (19-21) and for wastage reduction of excess formulation for expensive monoclonal antibodies (e.g., oncology) (12). The relative simplicity of this practical MIPD implementation makes it suitable for healthcare implementation, albeit care should be taken to prevent impractical dosing administration intervals and subsequent prescribing errors. An example of wide-spread implementation of model-derived dosage regimens is the Dutch Paediatric Formulary (3). This nation-wide web-based formulary presents dosing guidelines for over 650 drugs prescribed to children. The dosing guidelines are based on the summary of product characteristics or in case of off-label use, best evidence from the scientific literature and expert consensus. Published literature is monitored routinely, and papers including new pharmacokinetic and/or pharmacodynamic data are evaluated for additional evidence to update guidelines. This has resulted in the implementation of model-derived dosing guidelines for e.g., vancomycin, gentamycin, tobramycin and amikacin based on age and weight. In some cases, the dosing intervals and/or doses were slightly adjusted to comply with computer-based prescribing systems or to prevent calculation mistakes. The model-derived dosing guidelines for morphine have not been implemented to date, as no consensus has been reached on its general applicability given the potentially different doses for different types of surgery (cardiac vs. non-cardiac surgery) or different subgroups (preterm vs. term neonates). A recent example in this respect is necrotising enterocolitis in preterm neonates, an extremely painful clinical situation, for which substantially higher morphine target concentrations were found necessary (63) .
There are several reasons associated with data collection as to why MIPD has not yet delivered its full potential. MIPD is data driven, relying on the individual patient's current characteristics and clinical data, prior information on physiology to inform systems parameters, drug and formulation-specific properties. In many instances one or several elements of the necessary data to inform the modelling is missing. The lack of publicly available clinical data means that interpretation of data is based on trends in central tendency between healthy and special patient populations rather than the ability to base analysis on individual patient data. With a few exceptions, there is a general lack of routine genotypic testing or usage of metabolic markers to inform individualised dosing. Further, there is a need for fully validated drug databases with consistent data regarding drug-specific properties (e.g., proportional importance of various elimination routes) and a more detailed and quantitative understanding of the physiology in special populations.
In the pharmaceutical industry, some progress has been made to enable sharing of clinical data (64).
These models for data sharing provide gated access subject to the proposed analysis and mostly do not include historical data. This may be viewed as a problematic approach as it is prone to dissemination bias (65). Other efforts are underway to address this issue. Some efforts are also being made to collate patient data at a wider scale, the most prominent example being the Precision Medicine Initiative, aiming to collect data from over one million volunteers (9).
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FUTURE LANDSCAPE: IMPLEMENTATION OF PRECISION DOSING IN HEALTHCARE
Although there are certainly cases of MIPD implementation in healthcare these mostly exist as isolated local efforts in collaboration between academia and clinical champions in individual hospitals or hospital departments (19, 21, 24, 36, 51-55). In order for MIPD to be more generally adopted in healthcare, locally and nationally, challenges must be addressed systematically. There are geographic and medical speciality cultural differences between healthcare professionals and the modelling community that hamper the exchange of knowledge and ideas on precision dosing. The decline in clinical pharmacology as a medical speciality, as seen in the United Kingdom, which could bridge the gap has not helped (66). However, the increasing clinical responsibilities given to clinical pharmacists would facilitate a natural link between pharmacokinetics, pharmacodynamics, systems pharmacology and clinical practice (67, 68). There is therefore a great need to educate and train healthcare professionals, both at a pre-graduate level and those working in practice, in the disciplines of quantitative clinical pharmacology and pharmacometrics, in order for model-informed approaches to gain traction in healthcare, whether employed independent of the modellers via smart systems (Apps on smartphones, tablets, or hospital systems) or in conjunction with modellers (particularly for more complex cases). Similarly, academic researchers should recognise wider impacts of their research at an early stage and plan towards monitoring and recording the necessary data to demonstrate such effects (for the purpose of assessing cost-benefit and beyond the mere treatment outcome). It is recognised that this may happen only through interactions and learning between science and practice otherwise presentations within academic groups may be seen as preaching to the choir, where academic research has produced many publications on dose individualisation that has yet to be translated into clinical dosing tools. To be able to target clinicians, clinical pharmacists, healthcare providers, patients and relatives it will also be necessary to provide additional evidence on the health economics of the specific context. Specifically, the questions and open issues that MIPD is required to solve need to be unambiguously clarified for each treatment area. Further, advocates of MIPD in healthcare need to engage with patient groups, such as HIV and cancer patient groups to facilitate data collection, transfer of patient information as well as advocating the need for a MIPD paradigm through increasing the awareness amongst patients regarding the impact of individual characteristics on dose requirements. It is essential that both healthcare professionals and patients feel included and own the process rather than it being something that is imposed. Prospective clinical evaluation is one of the cornerstones to enable this, by showing concordance between predicted and observed exposure/efficacy/toxicity at both a population and individual level, in scenarios of relatively narrow therapeutic indices, where the risk of toxicity of sub-therapeutic treatment is relatively high and in vulnerable patient populations (Figure 2) .
Although rare, few MIPD efforts to date have been associated with defined health-economic achievements (51, 52, 56). However, even when such information is available, communicating them to the management in healthcare is not an easy task. Engaging with healthcare management and healthcare providers (insurance companies/national healthcare organisations) to support the concept of MIPD necessitates not only the formal evaluation of the financial significance and added value in terms of patient benefit and satisfaction but also communicating in an effective and unambiguous manner. Investigators working in MIPD should strive for prospective assessment of improved patient outcomes and not limit themselves to optimising observed pharmacokinetics/dynamics alone, even though this will raise the costs of the studies. The modelling community, working together with clinicians, need to generate proof of concept for MIPD in a number of key clinical centres to generate critical mass of evidence that encourages wider adoption.
In order for MIPD models to be prospectively evaluated it is paramount that funding be available for collaboration between clinicians and the modelling community. The validation of previously published models in a larger scale may not be viewed as a sufficiently novel research activity for funding agencies. However, the increased attention given to rigor and reproducibility suggest that model validation is imperative. Further, the scene on 'improvement science' (exploring how to efficiently change methods to increase quality improvements) in healthcare is changing and most There is no prescriptive measure of what the level of provided benefit need be against the standard of care in order for MIPD to succeed, as marginal gains depend on the size of the patient population.
One should remember that the standard of care, depending on the speciality and the experience of the physician, has some degree of personalised dosing through the process we coined as 'in cerebro' modelling and integration of prior knowledge, albeit not uniformly. In a large population, e.g., patients treated with statins (69), a minor gain in benefit may translate into a significant improvement in drug therapy for a considerable number of patients and subsequent costs savings for healthcare providers and payers.
On a more practical aspect, the availability of drug-specific formulations and dose strengths will determine the short-term feasibility of implementing MIPD in healthcare. 
REQUIREMENTS FOR MODEL-INFORMED PRECISION DOSING TOOLS
As discussed above, for any MIPD tool due attention needs to be given to the financial model under which they would be developed and implemented. This should consider issues such as liability were anything to go wrong. This process would have to ensure that the design, validation, and implementation are transparent and that the output strikes an appropriate balance between uses and the inherent risks associated with any extrapolative process. Several streams or scenarios for developing these tools would be possible, e.g., through the pharmaceutical industry, research institutions, healthcare institutions, by clinicians themselves, patient advocacy groups or other for profit entities. Ideally a joint process across multiple partners would ensure that the above transparency, risk and use balances are appropriately struck. There may also be an opportunity to expand usage or extend patent protections and market exclusivities using an innovative drug/tool combination. These potential benefits could motivate not only research with new active moieties, but also research approved medications which could benefit from improved dosing regimens. For example there may be instances where initial approval on basic dosing and a subsequent approval include an MIPD based dosing strategy with an associated marketing authorisation for use of MIPD software. Also, as mentioned earlier, model-based approaches may likely prove most useful in patient groups where polypharmacy (and thus DDIs) and/or multiple co-morbidities are present, such as the treatment of cardiovascular disease, cancers and infectious disease in the elderly, and for which disease-related outcomes and drug adverse effects are relatively frequent with large amount of data that can be made available. As data are gathered in the post-market setting after an initial drug or biological product approval, those data could inform development of software models that integrate what is discovered in the market, and ultimately lead to supplemental marketing authorisations that reflect reliance on an MIPD-based dosing strategy.
Ultimately, these potential rewards for research could motivate further investment as MIPD research advances to the ultimate benefit of patients. However, engagement with regulatory authorities, both individually on product-specific application and as stakeholders more generally, will be essential because of the intricacies that can be involved in combination and complementary-use product regulation. There is also a case for providing incentives to pharmaceutical industry to enable broader dose guidance at time of approval, including the MIPD companion tool approach highlighted here. 
DISCUSSION
